Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.

@article{Fu2015PhaseIS,
  title={Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.},
  author={S. Kristine Fu and M M Hou and Aung S. Naing and Filip Janku and Kenneth Hess and Ralph G. Zinner and Vivek Subbiah and David S. Hong and Jennifer J. Wheler and Sarina Anne Piha-Paul and A Tsimberidou and Daniel Karp and D{\'e}bora Helo{\'i}sa Quadros Ara{\'u}jo and Bryan K. Kee and Patrick Hwu and Robert A. Wolff and Razelle Kurzrock and Funda Meric-Bernstam},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2015},
  volume={26 5},
  pages={1012-8}
}
BACKGROUND We carried out a phase I trial of the vascular endothelial growth factor inhibitor pazopanib and the histone deacetylase inhibitor vorinostat to determine the safety and efficacy. Because these agents are known to target factors activated by TP53 mutation and facilitate mutant p53 degradation, a subgroup analysis may be interesting in patients with TP53 mutant malignancies. PATIENTS AND METHODS Patients with advanced solid tumors (n = 78) were enrolled following a 3 + 3 design… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…